ORIC Pharmaceuticals Inc. (ORIC)
4.77
0.08 (1.71%)
At close: Apr 17, 2025, 3:59 PM
4.89
2.58%
After-hours: Apr 17, 2025, 07:50 PM EDT
1.71% (1D)
| Bid | 4.5 |
| Market Cap | 338.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -127.85M |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -2.61 |
| Forward PE | -2.44 |
| Analyst | Buy |
| Ask | 5.29 |
| Volume | 531,982 |
| Avg. Volume (20D) | 1,068,090 |
| Open | 4.76 |
| Previous Close | 4.69 |
| Day's Range | 4.59 - 4.78 |
| 52-Week Range | 3.90 - 14.67 |
| Beta | 1.37 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; an...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 115
Stock Exchange NASDAQ
Ticker Symbol ORIC
Website https://www.oricpharma.com
Analyst Forecast
According to 9 analyst ratings, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 319.29% from the latest price.
Stock Forecasts1 month ago
+2.72%
Oric Pharmaceuticals shares are trading higher. JP...
Unlock content with
Pro Subscription
5 months ago
-0.42%
Oric Pharmaceuticals shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a price target of $17.
